Work

A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.

Year: 2002

Type: article

Study design: Clinical Trial

Source: PubMed

Authors: Gini F Fleming, Neal J Meropol, Gary L Rosner, Donna R Hollis, William E Carson, Michael Caligiuri, Joanne Mortimer, Katherine Tkaczuk, Robin Parihar, Richard L Schilsky, Mark J Ratain

Institutions: University of Chicago, Fox Chase Cancer Center, Duke University, The Ohio State University, Washington University in St. Louis, University of Maryland, Baltimore

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

Awards: CANCER AND LEUKEMIA GROUP B--PET COMMITTEE, Cancer and Leukemia Group B

OpenAlex ID: W2164322153

FWCI: 1.097

Cites: 16

Cited by: 52

Related to: 10